Characterizing Cefepime Neurotoxicity: A Systematic Review
Author(s) -
Ayesha Appa,
Rupali Jain,
Robert M. Rakita,
Shahin Hakimian,
Paul S. Pottinger
Publication year - 2017
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofx170
Subject(s) - cefepime , medicine , neurotoxicity , status epilepticus , encephalopathy , incidence (geometry) , myoclonus , pediatrics , level of consciousness , intensive care medicine , anesthesia , epilepsy , psychiatry , ceftazidime , toxicity , genetics , physics , bacteria , optics , pseudomonas aeruginosa , biology
Neurotoxicity due to cefepime has not been well characterized. We performed a systematic review of the literature and included 5 additional cases from our center. Of the 198 cases found, the mean age was 67 years and 87% of patients had renal dysfunction. The most common clinical features were diminished level of consciousness (80%), disorientation/agitation (47%), and myoclonus (40%). It is worth noting that nonconvulsive status epilepticus was relatively common with 31% of cases, whereas only 11% had convulsive seizures. Single-center estimate of incidence was 1 in 480 courses of cefepime. Cefepime neurotoxicity should be considered in older patients with renal dysfunction and new onset encephalopathy, especially if concurrent myoclonus is present. More work is needed to prospectively assess incidence and outcomes related to cefepime neurotoxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom